OncoMethylome Sciences licenses methylation technologies to Qiagen for commercializing epigenetic applications
Herman Spolders, Chief Executive Officer of OncoMethylome Sciences S.A. stated: "We are very pleased to have entered this relationship with QIAGEN, the market leader for sample and assay technologies in molecular diagnostics, applied testing, and pharmaceutical and academic research, which underscores the great value that OncoMethylome's technologies have for the epigenetic cancer research market. The agreement will lead to accelerated research in methylation-based applications for early detection and personalized treatment of cancer."
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.